Skip to main content

Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed)

Agency: National Institutes of Health

Assistance Listings
  • 93.350 -- National Center for Advancing Translational Sciences

Forecasted opportunityLast Updated: May 13, 2026

Important dates

  • Forecasted post date: January 16, 2026
  • Forecasted application due date: June 16, 2026
  • Forecasted award date: April 15, 2027
  • Forecasted project start date: April 15, 2027
  • Fiscal Year: 2027

Award details

  • Expected project funding: $1,600,000
  • Expected awards: 2

Award min.

Not specified

Award max.

Not specified

  • Funding opportunity number:RFA-TR-25-016
  • Cost sharing or matching requirement:No
  • Funding instrument type:
    • Cooperative agreement
  • Opportunity Category:Discretionary
  • Opportunity Category Explanation:Not specified
  • Category of Funding Activity:
    • Health
  • Category Explanation:Not specified

History

  • Forecast posted date: September 29, 2025
  • Archive date: Not specified
  • Version: 1

View version history on Grants.gov

Summary

NIH intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that will develop, validate and demonstrate the utility of advanced 3-D tissue models for testing the efficacy of various therapeutic modalities, including small molecules and biologics and accelerate the discovery and development of new therapeutics across different diseases.

The initiative will develop advanced 3-D drug screening models adaptable to high throughput assays. These non-animal models are expected to mimic structural, biochemical and mechanical properties of tissue that are representative of a drug’s behavior in a body, resulting in improved predictive accuracy. This is an expansion upon the work conducted under previous NOFOs, RFA-TR-17-007, RFA-TR-19-020 and RFA-TR-21-015, that have focused on development of 3-D skin and other tissue models for drug screening. The applicants are required to utilize the 3-D modeling/drug screening expertise and infrastructure available at the NCATS 3-D Bioprinting laboratory. 3-D tissue models in a well-based drug screening platform should be as complex as necessary to achieve physiological/pharmacological relevance, and as simple as possible to make the models robust, reliable and amenable to drug screening. Grant authorities that allow NCATS to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network.

Eligibility

Government

  • City or township governments
  • County governments
  • State governments
  • Special district governments
  • Public and Indian housing authorities
  • Federally recognized Native American tribal governments

Nonprofit

  • Nonprofits non-higher education with 501(c)(3)
  • Nonprofits non-higher education without 501(c)(3)
  • Other Native American tribal organizations

Business

  • Small businesses
  • For-profit organizations other than small businesses

Education

  • Independent school districts
  • Private institutions of higher education
  • Public and state institutions of higher education

Miscellaneous

  • Other

Additional information on eligibility

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-Eligible ApplicantsNon-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Documents

No documents are currently available.

Agency contact information

Email: dobrila.rudnicki@nih.gov

dobrila.rudnicki@nih.gov

Dobrila D. Rudnicki, Ph.D. 240-535-6621

Link to additional information

No additional information is available

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov